Does not seem to make any sense signing up distribution deals when very little product is funnelled through them. The limited amount of revenue seems a bit weak when every man and his dog has a distribution deal with MGC and there is less revenue accruing through these channels than there is paying BM's salary.
The confirmed CannEpil sales revenue will show whether they have a viable increasing income stream. That will be be an important marker in determining their future success going forward.
Ann: Brazil Distribution Agreement signed for MGC Pharma Products, page-29
Add RGT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
56.5¢ |
Change
0.060(11.9%) |
Mkt cap ! $27.34M | |||
| Open | High | Low | Value | Volume |
| 50.5¢ | 56.5¢ | 50.5¢ | $8.762K | 15.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 961 | 53.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.5¢ | 1389 | 1 |
View Market Depth
| Last trade - 14.14pm 08/10/2024 (20 minute delay) ? |
| RGT (ASX) Chart |